High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer.
Ketoconazole, an antifungal agent, inhibits in vitro C17-C20 lyase, an enzyme involved in androgen biosynthesis. Since adrenal and ovarian androgens are the main precursors of oestrogens in postmenopausal women, the endocrine and therapeutic effects of high dose ketoconazole (400 mg three times a da...
Main Authors: | Harris, A. L., Cantwell, B. M., Dowsett, M. |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
1988
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246803/ |
Similar Items
-
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
by: Harris, A. L., et al.
Published: (1983) -
Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
by: Harris, A. L., et al.
Published: (1989) -
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
by: Dowsett, M., et al.
Published: (1985) -
Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
by: Dowsett, M., et al.
Published: (1984) -
Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.
by: Millward, M. J., et al.
Published: (1991)